Literature DB >> 10946287

Mycobacterium tuberculosis infection in complement receptor 3-deficient mice.

C Hu1, T Mayadas-Norton, K Tanaka, J Chan, P Salgame.   

Abstract

Complement receptor type 3 (CR3) present on macrophages is used by Mycobacterium tuberculosis as one of its major phagocytic receptors. In this study, we examined the in vivo significance of CR3-mediated phagocytosis on the pathogenesis of disease caused by M. tuberculosis. The outcome of tuberculous infection in mice deficient in the CD11b subunit of CR3 (CR3-/-) on a mixed 129SV and C57BL background and control wild-type counterparts was comparable with respect to survival, bacterial burden, granulomatous lesion development, and cytokine expression in the spleen and lungs. M. tuberculosis infection was also examined in CR3-/- mice on C57BL/6 and BALB/c backgrounds and was found to be similar. In conclusion, our results suggest that in the absence of CR3, M. tuberculosis is able to gain entry into host cells via alternative phagocytic receptors and establish infection. The data also indicate that absence of CR3 does not alter disease course in either the relatively resistant C57BL/6 or the relatively susceptible BALB/c strains of mice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10946287     DOI: 10.4049/jimmunol.165.5.2596

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

Review 1.  The many faces of host responses to tuberculosis.

Authors:  H L Collins; S H Kaufmann
Journal:  Immunology       Date:  2001-05       Impact factor: 7.397

Review 2.  C-type lectins with a sweet spot for Mycobacterium tuberculosis.

Authors:  G Lugo-Villarino; D Hudrisier; A Tanne; O Neyrolles
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2011-03

Review 3.  Orchestration of pulmonary T cell immunity during Mycobacterium tuberculosis infection: immunity interruptus.

Authors:  Samuel M Behar; Stephen M Carpenter; Matthew G Booty; Daniel L Barber; Pushpa Jayaraman
Journal:  Semin Immunol       Date:  2014-10-11       Impact factor: 11.130

4.  The efficiency of the translocation of Mycobacterium tuberculosis across a bilayer of epithelial and endothelial cells as a model of the alveolar wall is a consequence of transport within mononuclear phagocytes and invasion of alveolar epithelial cells.

Authors:  Luiz E Bermudez; Felix J Sangari; Peter Kolonoski; Mary Petrofsky; Joseph Goodman
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

5.  Imatinib-sensitive tyrosine kinases regulate mycobacterial pathogenesis and represent therapeutic targets against tuberculosis.

Authors:  Ruth J Napier; Wasiulla Rafi; Mani Cheruvu; Kimberly R Powell; M Analise Zaunbrecher; William Bornmann; Padmini Salgame; Thomas M Shinnick; Daniel Kalman
Journal:  Cell Host Microbe       Date:  2011-11-17       Impact factor: 21.023

Review 6.  Mannose-capped lipoarabinomannan in Mycobacterium tuberculosis pathogenesis.

Authors:  Joanne Turner; Jordi B Torrelles
Journal:  Pathog Dis       Date:  2018-06-01       Impact factor: 3.166

Review 7.  C-type lectin receptors in tuberculosis: what we know.

Authors:  Surabhi Goyal; Tilman E Klassert; Hortense Slevogt
Journal:  Med Microbiol Immunol       Date:  2016-07-28       Impact factor: 3.402

8.  Complement protein C3 binding to Mycobacterium tuberculosis is initiated by the classical pathway in human bronchoalveolar lavage fluid.

Authors:  J Scott Ferguson; Jeremy J Weis; Jennifer L Martin; Larry S Schlesinger
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

9.  Differential gene expression in mononuclear phagocytes infected with pathogenic and non-pathogenic mycobacteria.

Authors:  J A McGarvey; D Wagner; L E Bermudez
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

Review 10.  Macrophages in tuberculosis: friend or foe.

Authors:  Evelyn Guirado; Larry S Schlesinger; Gilla Kaplan
Journal:  Semin Immunopathol       Date:  2013-07-18       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.